Companies › Granata Bio
1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| hMG (human menopausal gonadotropin) Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) receptor agonist | FSHR, LHR | Phase 3 | Infertility (IVF Patients) | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07216742 | hMG (human menopausal gonadotropin) | Phase 3 | Infertility (IVF Patients) | Genitourinary | Nov 2028 |
Fertility Center of Las Vegas Zydus Lifesciences Dimerix Bioscience Chengdu Qingshan Likang Pharmaceutical Hope Medicine (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.